<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

“…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". The following acronyms included in the CSV file are defined as follows: Hbt is total hemoglobin, Art is artery region, DV is draining vein region, WV is whisker vein region, SEM is standard error mean, TS is time series, max peak is maximum peak, min peak is minima, AUC is area under the curve, WT is wild-type, AD is Alzheimer's disease, ATH is atherosclerosis and MIX is mixed AD/atherosclerosis. …”

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

HSF2 reduced the decrease in the MMP in Caco-2 cells, which were observed by laser confocal microscopy. by Wen Wang (6570)

“…Red fluorescence indicated that there was no obvious abnormality in the MMP, while green fluorescence represented a decrease in the MMP. B: Statistical bar chart of the ratio of red to green fluorescence, <i>P</i> value of less than 0.05 was identified as* and <i>P</i> value of less than 0.01 was identified as**. …”

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  by Beatrice T. Nganso (4114768)

Subjects:

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…<b>(B)</b> Grand-averaged target-locked neural timescales (mean ± SEM; shaded gray area represents cue-target interval) for three ROIs. …”

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

Incorporating a social responsibility goal in the prompt causes overleverage in utilities (A) and decreases risk of low ESG rating (B) (Study 3). by Philipp Winder (21615570)

Volitional control frequency and intensity in VH (Kapsner-Smith et al., 2025) by Mara R. Kapsner-Smith (22139315)

“…<p dir="ltr"><b>Purpose: </b>Prior studies of vocal auditory–motor control in people with hyperfunctional voice disorders (HVDs) have found evidence of unusually large responses to auditory feedback perturbations of fundamental frequency (<i>F</i>0) and more variable voice onset times in unperturbed speech. …”

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

<b>When more isn’t better: Sperm competition decreases fertilization success and motile sperm in two sea urchin species</b> by Luisa Kumpitsch (20874095)

“…<p dir="ltr">Abstract of the paper "<b>When more isn’t better: Sperm competition decreases fertilization success and motile sperm in two sea urchin species":</b></p><p dir="ltr">Fertilization is a fundamental process where sperm-egg fusion is essential to maintain life of most metazoans. …”

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: